Briviact 10mg/ml oral solution
- Name:
Briviact 10mg/ml oral solution
- Company:
UCB (Pharma) Ireland Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 10/01/20
(Click to Download)Click on this link to Download PDF directly
UCB (Pharma) Ireland Limited
 Ireland Limited.jpg)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 10 January 2020 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Extension of shelf life for Oral solution and Solution for injection;
Implementing the new statements for excipients listed in the revised Annex to the European Commission guideline on "Excipients in the labelling and package
leaflet of medicinal products for human use" (SANTE-2017-11668) in the relevant sections of the SmPC, Labelling and Package Leaflet, as appropriate.
Updated on 10 January 2020 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Extension of shelf life for Oral solution and Solution for injection;
Implementing the new statements for excipients listed in the revised Annex to the European Commission guideline on "Excipients in the labelling and package
leaflet of medicinal products for human use" (SANTE-2017-11668) in the relevant sections of the SmPC, Labelling and Package Leaflet, as appropriate.
Updated on 24 July 2019 SmPC
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 1 August 2018 PIL
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 1 August 2018 SmPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Changes concerning the approval of Briviact in paediatric patients (>=4 years old)
Sections:
4.1. Therapeutic indications;4.4 Special warnings and precautions for use;4.8 Undesirable effects;5.1 Pharmacodynamic properties;5.2 Pharmacokinetic properties;10 Date of revision of the text
Updated on 18 July 2018 PIL
Reasons for updating
- Change to section 2 - use in children and adolescents
Updated on 26 April 2017 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.5 Interaction with other medicinal products and other forms of interaction
Editorial change
4.8 Undesirable effects
Type I hypersensitivity (Immune system disorders -Uncommon)
Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.
5.2 Pharmacokinetic properties
Biotransformation
[…] Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9). […]
Updated on 26 April 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 24 April 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 24 April 2017 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 27 March 2017 SmPC
Reasons for updating
- Previous version of SPC reinstated
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Previous version of SPC reinstated
Updated on 23 March 2017 PIL
Reasons for updating
- Previous version of PIL reinstated
Updated on 28 February 2017 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
In section 4.8 (undesirable effects), Type I hypersensitivity has been added with uncommon frequency
And the description of the above mentioned adverse reaction has been added as follow “Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.”
In section 5.2 (Biotransformation): “[…] Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9).”
Updated on 27 February 2017 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 16 December 2016 PIL
Reasons for updating
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 24 June 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 24 June 2016 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)